Notizie e Video - UNITED THERAPEUTICS - Pagina 2

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that the first patient has enrolled in the phase 3 TETON 2 study which will evaluate Tyvaso in 396 adult patients with idiopathic pulmonary fibrosis ( IPF ) at sites outside the United States and Canada. This second registration study is part of the broader global TETON program evaluating Tyvaso for the treatment of IPF. The 52-week study will evaluate the impact of Tyvaso on a key prognostic indicator...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation ( PBC ), today announced the release of its third annual Corporate Responsibility Report with 2021 highlights, providing stakeholders important information regarding the company’s commitment to environmental, social, and governance ( ESG ) priorities. Contained within the report is the company’s inaugural public benefit report, detailing United Therapeutics’ efforts to meet its public benefit purpose: to provide...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that the United States District Court for the District of Delaware issued an opinion in the pending litigation concerning United Therapeutics’ U.S. patents 9,593,066 (the ’066 patent ) and 10,716,793 (the ’793 patent ). This litigation concerns whether Liquidia Technologies, Inc.’s proposed treprostinil inhalation powder, Yutrepia TM , would infringe the ’066 and ’793 patents. The Court...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that four posters and one oral presentation will be presented at the European Society of Cardiology ( ESC ) Congress 2022, taking place August 26-29, 2022, and the European Respiratory Society ( ERS ) International Congress 2022, taking place September 4-6, 2022. Both congresses will be held in Barcelona, Spain. The presentation and posters describe completed and ongoing clinical studies of Tyvaso ®...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2022. Total revenues in the second quarter of 2022 grew 5% year-over-year to $466.9 million, compared to $446.5 million in the second quarter of 2021. “I’m extraordinarily pleased with our business performance this past quarter,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. “The FDA’s...

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2022 financial results before the market opens on Wednesday, August 3, 2022. United Therapeutics will host a public webcast Wednesday, August 3, 2022, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations . A rebroadcast of the webcast will be available for one week and can be accessed at the same location....

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that in partnership with 3D Systems Corporation (NYSE: DDD ) it has produced the world’s most complex 3D-printed object – a human lung scaffold – and demonstrated it at the LIFE ITSELF Conference that occurred May 31 to June 3, 2022 in San Diego. The event was organized and hosted by Dr. Sanjay Gupta and Marc Hodosh and was sponsored by CNN, United Therapeutics, and other prominent corporate...

United Therapeutics Corporation (Nasdaq: UTHR ) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company’s business during a fireside chat session at the Jefferies Healthcare Conference in New York City. The session will take place virtually on Thursday, June 9, 2022, from 11:00 a.m. to 11:25 a.m., Eastern Daylight Time, and can be accessed via a live webcast on the United Therapeutics website at...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the U.S. Food and Drug Administration ( FDA ) has approved Tyvaso DPI™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension ( PAH ; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease ( PH-ILD ; WHO Group 3) to improve exercise ability. Tyvaso DPI represents a new formulation and inhalation device for inhaled treprostinil and is the...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2022. Total revenue in the first quarter of 2022 grew 22% year-over-year to $461.9 million, compared to $379.1 million in the first quarter of 2021. “The hard work and dedication of our Unitherians has resulted in double-digit percentage revenue growth year-over-year for Tyvaso, Orenitram, Unituxin, and our total treprostinil portfolio, along with...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that eight posters and three mini-symposia across the company’s commercial and development portfolio will be presented at the 2022 American Thoracic Society ( ATS ) International Conference, taking place May 13-18, 2022, in San Francisco. In addition, the company is hosting a sponsored symposium on pulmonary hypertension associated with interstitial lung disease ( PH-ILD ) and is sponsoring the ATS...

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2022 financial results before the market opens on Wednesday, May 4, 2022. United Therapeutics will host a public webcast Wednesday, May 4, 2022, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations . A rebroadcast of the webcast will be available for one week and can be accessed at the same location. United...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the publication of additional clinical and long-term safety data from the BREEZE study evaluating Tyvaso DPI™ (treprostinil) in patients with pulmonary arterial hypertension ( PAH ) in the journal Pulmonary Circulation . The publication evaluated the BREEZE study and its ongoing optional extension phase ( OEP ), and concluded: Tyvaso DPI’s delivery device, along with the clinical results from BREEZE...

United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company’s business during a fireside chat session at the Oppenheimer 32 nd Annual Healthcare Conference. The session will take place virtually on Tuesday, March 15, 2022, from 9:20 a.m. to 9:50 a.m., Eastern Daylight Time, and can be accessed via a live webcast on the United Therapeutics website at...

United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company’s business during a fireside chat session at the Cowen 42 nd Annual Health Care Conference. The session will take place virtually on Tuesday, March 8, 2022, from 11:10 a.m. to 11:40 a.m., Eastern Standard Time, and can be accessed via a live webcast on the United Therapeutics website at...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the fourth quarter and year ended December 31, 2021. Full year total revenues rose to $1,686 million, as U.S. patients being treated with the company’s treprostinil-based therapies reached an all-time high during the fourth quarter of 2021. “We continue to make strong progress with patient growth as we march toward our target of reaching 25,000 patients with our therapies...

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2021 financial results before the market opens on Thursday, February 24, 2022. United Therapeutics will host a public webcast Thursday, February 24, 2022, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations . A rebroadcast of the webcast will be available for one week and can be accessed at...

United Therapeutics Corporation ( UT ) (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, announced today that the world's first recipient of an investigational genetically-modified xenotransplanted organ, UT’s UHeart™, reached a two-week milestone. University of Maryland School of Medicine ( UMSOM ) surgeons report continued post-operative cardiovascular improvement in the patient with normal organ function. In addition, the first...

United Therapeutics Corporation (Nasdaq: UTHR) announced today that Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer, and Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, will provide an overview and update on the company’s business during a fireside chat conversation hosted by J.P. Morgan biotechnology analyst Jessica Fye. The conversation will take place virtually on Thursday, January 6, 2022, from 8:00 a.m. to 8:45 a.m., Eastern Standard...

United Therapeutics (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today announced that the company has been named on Newsweek’s list of America’s Most Responsible Companies 2022. This award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. The awards list was announced on December 2, 2021, available on Newsweek’s website , recognizes the top 500 most responsible companies...